Compare Elevance Health Inc. Common Stock (ELV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Elevance Health (ELV) trades at $425.27, up 0.75% with a bullish technical outlook and strong institutional support. The stock shows consistent earnings beats with Q1 2026 EPS of $12.58 beating expectations by 16%, while maintaining solid fundamentals with $199.13B revenue and 11.2% ROE. Recent Medicare Advantage plan announcements and positive analyst coverage reinforce growth prospects.

ELV presents a compelling investment case with 71% analyst buy ratings and $445.13 price target offering 4.7% upside. However, declining 2026 profit margins to 2.46% and regulatory uncertainty in healthcare sector pose risks. The stock's current valuation at 18.81 P/E appears reasonable given earnings momentum and market position.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.